Daré Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 23, 2026 (with events reported through January 27, 2026), details the initial closing of a Regulation A offering by Daré Bioscience, Inc. The company filed a Certificate of Designation for Series A Convertible Preferred Stock with the Delaware Secretary of State on January 23, 2026, in anticipation of the offering.
Key Financial Metrics and Capital Structure
The filing discloses the following capital raising metrics and terms:
- Offering Structure: Sale of up to 4,854,000 Investor Units at $5.00 per unit.
- Unit Composition: Each unit consists of one share of Series A Convertible Preferred Stock and two warrants to purchase one share of Common Stock.
- Initial Closing Proceeds: 5,090 Investor Units were issued at the initial closing on January 27, 2026, generating gross proceeds of approximately $25,450 (5,090 units x $5.00).
- Preferred Stock Terms:
- Stated Value: $5.00 per share.
- Liquidation Preference: $5.00 per share (senior to Common Stock).
- Dividends: None.
- Conversion Price: $2.50 per share of Common Stock (1 Preferred share converts to 2 Common shares).
- Company Call Option: Available after the third anniversary at a price equal to the lesser of stated value plus 8% non-compounded annual return or 200% of stated value.
- Warrant Terms:
- Investor Warrants: Exercise price of $4.00 per share; exercisable for 36 months.
- Agent Warrants: Issued to the selling agent (Digital Offering, LLC) at 3% of units sold; exercise price of $6.25 per Agent Unit (which includes preferred stock and warrants).
- Transaction Costs:
- Placement Fee: 7.25% of the offering price per unit sold.
- Consulting Fee: $25,000 paid to Digital Offering.
- Expense Reimbursement: Up to $85,000 for out-of-pocket expenses.
Note: The filing does not provide data on total revenue, net profit, operating cash flow, or existing debt levels. The company had no preferred stock outstanding prior to this offering.
Material Changes
The primary material change is the authorization and initial issuance of Series A Convertible Preferred Stock. Prior to this filing, the company had no preferred stock outstanding. The issuance of 5,090 units at the initial closing represents the first tranche of a "best efforts" offering intended to raise capital through multiple rolling closings.
Outlook, Risks, and Contingencies
- Offering Duration: The offering will terminate on the earliest of: (i) the sale of the maximum 4,854,000 units, (ii) January 5, 2027, or (iii) a date determined by the company.
- Forced Conversion Triggers: The company may force conversion of Preferred Stock to Common Stock if:
- A change in control occurs.
- The Common Stock closing price is at or above $4.50 for 10 out of 30 consecutive trading days.
- The company consummates a firm commitment public offering of Common Stock with gross proceeds of at least $15.0 million at an offering price of $4.50 or higher.
- Nasdaq Listing Rules: The filing notes that because the initial conversion price ($2.50) exceeded the sum of the common stock closing price ($1.90) plus $0.125, specific Nasdaq Listing Rule 5635(d) limitations regarding stockholder approval for conversion do not apply to the initial tranche.
- Liquidity Risk: The Investor Units, Preferred Stock, and Warrants are not listed on any exchange and are not intended to be listed.
Key Facts for Investor Verification
- Verify the total number of Investor Units sold in subsequent closings to assess total capital raised against the $24.27 million maximum potential (4,854,000 units x $5.00).
- Monitor the Common Stock trading price relative to the $4.50 forced conversion trigger and the $2.50 conversion price.
- Confirm the dilution impact of the 10,180 warrants issued at the initial closing and the potential 9,708,000 warrants (2 per unit) if the full offering is sold.
- Review the company's cash burn rate and runway, as the filing does not disclose current cash balances or operating expenses.
- Check for any future filings regarding the exercise of the Company Call Option on the Preferred Stock after the third anniversary of the initial closing.